Non-invasive assessment of tumour cell proliferation with positron emission tomography and [76Br]bromodeoxyuridine

Melanoma Research

Volumn 9, Issue 6, 1999, Pages 569-573

  Boni R ^a   Blauenstein P ^b   Dummer, R ^a   Von Schulthess, G K ^a   Schubiger, P A ^b   Steinert, H C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Bromodeoxyuridine; Melanoma; Positron emission tomography; Proliferation

Indexed keywords

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE TARGETING; HUMAN; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

EID: 0033429251     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199912000-00005     Document Type: Article

References (20)

1. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
2. Warburg O. The Metabolism of Tumors. New York: Smith RR, 1931: 129-169.
3. Böni R, Huch Böni RA, Steinert H, Burg G, Buck A, Marincek B, Berthold T, Dummer R, Voellmy D, Ballmer B, von Schulthess GK. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-562.
4. Steinert HC, Huch Böni RA, Buck A, Böni R, Berthold T, Marincek B, Burg G, von Schulthess GK. Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
5. Epstein WL, Maibach HI. Cell renewal in human epidermis. Arch Dermatol 1965; 92: 462-468.
6. Abe Y, Fukuda H, Ishiwata K, et al. Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals. Eur J Nucl Med 1983; 8: 258-261.
7. 3H)thymidine, and gallium-67. J Nucl Med 1991; 32: 2118-2123.
8. Sawhney N, Hall PA. Ki67 - structure, function and new antibodies. J Pathol 1992; 168: 161-162.
9. Böni R, Doguoglu A, Burg G, Müller B, Dummer R. MIB-I immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996; 35: 416-418.
10. 76Br] bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. J Nucl Med Biol 1999 (in press).
11. Aukerman SL, Fidler IJ. The heterogeneous nature of metastatic neoplasms: relevance to biotherapy. In: Oldham RK, ed. Principles of Cancer Biotherapy. New York: Marcel Dekker, 1991: 23-53.
12. Fidler IJ. Critical factors in the biology of human cancer metastasis. Cancer Res 1990; 50: 6130-6138.
13. Shields AF, Coonrod DV, Quackenbush RC, Crowley JJ. Cellular sources of thymidine nucleotides: studies for PET. J Nucl Med 1990; 28: 1435-1440.
14. Kriss JP, Révész L. The distribution and fate of bromodeoxyuridine and bromodeoxycytidine in the mouse and rat. Cancer Res 1962; 22: 254-265.
15. Goethals P, Lameire N, van Eijkeren M, Kosteloot D, Thierens H, Dams R. [Methyl-11C]thymidine for in vivo measurement of cell proliferation. J Nucl Med 1996; 37: 1048-1052.
16. Tjuvajev J, Muraki A, Ginos J, Berk J, Koutcher J, Ballon D, Beattie B, Finn R, Blasberg R. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 1993; 34: 1152-1162.
17. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labelled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990; 31: 337-342.
18. 11C]thymidine and its metabolites in head and neck tumors. J Nucl Med 1995; 36: 880-882.
19. 131I-5-iodo-2-deoxyuridine by malignant tumours in man. Br J Cancer 1991; 63: 134-135.
20. Lawrence TS, Davis, MA, Maybaum J, Mukhopadhyay DP, Stetson PL, Normolle DP, McKeever PE, Ensminger WD. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res 1992; 52: 3698-3704.